Life Sciences

Life Sciences

  • Tetra Bio-Pharma
    Tetra Bio-Pharma: The Canadian Pioneer in Cannabis-Based Pharma for Pain Relief in Cancer Patients
    May 16, 2017 by
    Tetra Bio-Pharma: The Canadian Pioneer in Cannabis-Based Pharma for Pain Relief in Cancer Patients Momentum Public Relations May 16, 2017 Momentum PR ‘s client, Tetra Bio-Pharma is listed on the Canadian Securities Exchange under the symbol TBP as well as on the OTCQB in the US under the […]...
    Read more
  • Tetra Bio-Pharma
    Tetra Bio-Pharma Strengthens Management Team
    May 11, 2017 by
    Tetra Bio-Pharma Strengthens Management Team   OTTAWA, ONTARIO–(Marketwired – May 10, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (CSE:TBP)(CSE:TBP.CN)(OTCQB:GRPOF), today announced that it has strengthened its management team with the appointment of Robert Bechard to the position of Vice President, Finance and Business Development, effective […]...
    Read more
  • Tetra Bio-Pharma
    Momentum Reports – Tetra Bio-Pharma CSE:TBP – April 2017
    May 2, 2017 by
    Momentum Reports – Tetra Bio-Pharma CSE:TBP – April 2017    ...
    Read more
  • Tetra Bio-Pharma Accelerates Sales Strategy with the Appointment of Denis Courchesne as Vice President, Sales
    Tetra Bio-Pharma Accelerates Sales Strategy with the Appointment of Denis Courchesne as Vice President, Sales
    April 24, 2017 by
      Tetra Bio-Pharma Accelerates Sales Strategy with the Appointment of Denis Courchesne as Vice President, Sales   OTTAWA, ONTARIO–(Marketwired – April 24, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP) (OTCQB:GRPOF), today announced that it has accelerated its sales strategy by entering into an employment […]...
    Read more
  • Tetra Bio-Pharma & Aphria Announce Plans for the Joint Distribution of Dried Medical Cannabis
    Tetra Bio-Pharma & Aphria Announce Plans for the Joint Distribution of Dried Medical Cannabis
    April 19, 2017 by
    Tetra Bio-Pharma & Aphria Announce Plans for the Joint Distribution of Dried Medical Cannabis in the Maritime Provinces & Quebec Momentum Public Relations Press Release: April 19, 2017 Tetra Bio-Pharma Inc. (“Tetra”) (CSE:TBP)(CSE:TBP.CN)(OTCQB:GRPOF) and Aphria Inc. (“Aphria”) (TSX:APH) (OTCQB:APHQF), announced plans today for the joint distribution of […]...
    Read more
  • Tetra Bio-Pharma Announces the Opening of a New Brunswick Office for Manufacturing & Sales Activities
    Tetra Bio-Pharma Announces the Opening of a New Brunswick Office for Manufacturing & Sales Activities
    April 12, 2017 by
      Tetra Bio-Pharma Announces the Opening of a New Brunswick Office for Manufacturing & Sales Activities   Momentum Public Relations Press Release: April 12, 2017 OTTAWA, ONTARIO–(Marketwired – April 12, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (CSE:TBP)(CSE:TBP.CN)(OTCQB:GRPOF) announced today it has opened an office […]...
    Read more
  • International Wastewater installs SHARC system at False Creek
    International Wastewater installs SHARC system at False Creek
    April 12, 2017 by
      International Wastewater installs SHARC system at False Creek   Momentum Public Relations Press Release: April 12, 2017 International Wastewater Systems Inc (C:IWS) Shares Issued 95,623,894 Last Close 4/11/2017 $0.22 Wednesday April 12 2017 – News Release Mr. Lynn Mueller reports IWS COMPLETES METRO VANCOUVER INSTALLATION International […]...
    Read more
  • Tetra Bio Pharma to begin trading on OTCQB April 6
    Tetra Bio Pharma to begin trading on OTCQB April 6
    April 6, 2017 by
      Tetra Bio Pharma to begin trading on OTCQB April 6   Momentum Public Relations Press Release: April 06, 2017 2017-04-05 16:10 ET – News Release. Mr. Andre Rancourt reports TETRA BIO-PHARMA UPGRADES TO OTCQB TO ENGAGE AND EXPAND U.S. INVESTOR AUDIENCE Effective tomorrow, shares of Tetra Bio Pharma […]...
    Read more
  • The Fountain of Youth
    Sirona Biochem (SBM:tsxv) Announces Keloid Data Accepted for Presentation to the Society of Investigative Dermatology
    April 5, 2017 by
    Sirona Biochem Announces Keloid Data Accepted for Presentation to the Society of Investigative Dermatology (SID) Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the “Company“) announced today that it has been accepted to present recent data at the 76th Annual Society of Investigative Dermatology (SID) […]...
    Read more
  • HealthSpace (HS:CSE) CEO Provides Update
    HealthSpace (HS:CSE) CEO Provides Update
    April 3, 2017 by
    HealthSpace CEO Provides Update Momentum Public Relations Press Release: April 3, 2017 HealthSpace Data Systems Ltd. (the “Company” or “HealthSpace”) is pleased to provide an update of the Company. Peter C. Smyrniotis, CEO of Healthspace comments, “I am pleased to provide an update on the progress of our […]...
    Read more
  • Tetra Bio-Pharma and IntelGenx Announce the Signing of a Definitive Agreement for the Development and Commercialization of a Dronabinol XL Tablet
    Tetra Bio-Pharma and IntelGenx Announce the Signing of a Definitive Agreement for the Development and Commercialization of a Dronabinol XL Tablet
    April 3, 2017 by
    IntelGenx and Tetra Bio-Pharma Announce the Signing of a Definitive Agreement for the Development and Commercialization of a Dronabinol XL Tablet Tetra Bio-Pharma Inc. (“Tetra“) (CSE:TBP)(OTC PINK:GRPOF) and  IntelGenx Corp. (“IntelGenx”) (TSX VENTURE:IGX)(OTCQX:IGXT), today announced the signing of a definitive agreement for the development and commercialization of […]...
    Read more
  • Tetra Bio-Pharma (TBP:CSE) Appoints Edward Miller as Vice President, Investor Relations & Corporate Communications
    Tetra Bio-Pharma (TBP:CSE) Appoints Edward Miller as Vice President, Investor Relations & Corporate Communications
    March 27, 2017 by
    Tetra Bio-Pharma Appoints Edward Miller as Vice President, Investor Relations & Corporate Communications – Momentum Public Relations – Press Release: March 27, 2017 Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(OTC PINK:GRPOF), today announced that it entered into an employment agreement with Edward Miller as Vice President, […]...
    Read more
  • HealthSpace (HS:CSE) Announces Contract with KFL&A Public Health and Issues Stock Options
    HealthSpace (HS:CSE) Announces Contract with KFL&A Public Health and Issues Stock Options
    March 9, 2017 by
    HealthSpace (HS:CSE) Announces Contract with KFL&A Public Health and Issues Stock Options – Momentum Public Relations – Press Release: March 9, 2017 HealthSpace Data Systems Ltd . (the “Company” or “HealthSpace”) is pleased to announce that the Company has signed a three-year contract, with renewal options, to […]...
    Read more
  • The Fountain of Youth
    Rising Popularity of Anti-Wrinkle Products Fuels Asia, Europe, and South America Anti-Aging Market
    March 3, 2017 by
    Rising Popularity of Anti-Wrinkle Products Fuels Asia, Europe, and South America Anti-Aging Market This press release was orginally distributed by SBWire Albany, NY — (SBWIRE) — 02/13/2017 — A new Transparency Market Research report states that the Asia, Europe, and South America anti-aging market was valued at US$15.3 […]...
    Read more
  • Tetra Bio-Pharma (TBP:CSE) Announces the Initiation of its Phase I Trial of PPP001 (dried Cannabis)
    Tetra Bio-Pharma (TBP:CSE) Announces the Initiation of its Phase I Trial of PPP001 (dried Cannabis)
    February 23, 2017 by
    Tetra Bio-Pharma Announces the Initiation of its Phase I Trial of PPP001 (dried Cannabis) – Momentum Public Relations – Press Release: February 23rd, 2017 PhytoPain Pharma (PPP), a subsidiary of Tetra BioPharma Inc. (“Tetra” or the “Company”) (CSE:TBP)(CSE:TBP.CN)(OTC PINK:GRPOF), a pharmaceutical company focused on developing and commercializing […]...
    Read more
  • Tetra Bio-Pharma Reports Approval by Health Canada of its Phase I Trial of PPP001 (dried Cannabis)
    Tetra Bio-Pharma Reports Approval by Health Canada of its Phase I Trial of PPP001 (dried Cannabis)
    February 16, 2017 by
    Tetra Bio-Pharma Reports Approval by Health Canada of its Phase I Trial of PPP001 (dried Cannabis) – Momentum Public Relations – Press Release: February 16, 2017 PhytoPain Pharma Inc. (PPP), a subsidiary of Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (CSE:TBP)(CSE:TBP.CN), a pharmaceutical company focused on developing […]...
    Read more
  • The 2017 Standards of Medical Care in Diabetes: an update from the ADA
    The 2017 Standards of Medical Care in Diabetes: an update from the ADA
    February 2, 2017 by
    The 2017 Standards of Medical Care in Diabetes: an update from the ADA   The American Diabetes Association (ADA) has released the 2017 update to its Standards of Medical Care in Diabetes (Standards).1 The document is reviewed each year by a multidisciplinary committee of experts in diabetes care, […]...
    Read more
  • Tetra Bio-Pharma Inc. (TBP:CSE) Completes Pre-IND Meeting with Food and Drug Administration on PPP001
    Tetra Bio-Pharma Inc. (TBP:CSE) Completes Pre-IND Meeting with Food and Drug Administration on PPP001
    January 30, 2017 by
    Tetra Bio-Pharma Inc. (TBP:CSE) Completes Pre-IND Meeting with Food and Drug Administration on PPP001 – Momentum Public Relations – Press Release: January 30th, 2017 PhytoPain Pharma Inc. (“PPP“), a subsidiary of Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(OTC PINK:GRPOF), a pharmaceutical company focused on developing and […]...
    Read more
  • Tetra BioPharma (TBP:CSE) Announces it Has Entered into a Clinical Research Partnership with Sante Cannabis, Quebec's Leading Medical Cannabis Institution
    Tetra BioPharma (TBP:CSE) Announces it Has Entered into a Clinical Research Partnership with Sante Cannabis, Quebec’s Leading Medical Cannabis Institution
    January 23, 2017 by
    Tetra BioPharma Announces it Has Entered into a Clinical Research Partnership with Sante Cannabis, Quebec’s Leading Medical Cannabis Institution – Momentum Public Relations – Press Release: January 23, 2017 PhytoPain Pharma Inc. (“PPP“), a subsidiary of Tetra Bio-Pharma Inc. (“TetraBio” or the “Company” or “TBP“) (CSE:TBP)(CSE:TBP.CN) is […]...
    Read more
  • Tetra Bio-Pharma Achieves DTC Eligibility in the United States
    Tetra Bio-Pharma Achieves DTC Eligibility in the United States
    November 16, 2016 by
    Tetra Bio-Pharma Achieves DTC Eligibility in the United States – Momentum Public Relations – Press Releases: November 16, 2016 Tetra Bio-Pharma Inc. (“TetraBio” or the “Company“) (CSE:TBP) (CSE:TBP.CN) (OTC PINK:GRPOF) is pleased to announce that effective November 13, 2016, it has secured Depository Trust Company (DTC) eligibility for […]...
    Read more
  • Namaste Highlights Voting Results from Key US States and Grants Options
    Namaste Highlights Voting Results from Key US States and Grants Options
    November 9, 2016 by
    Namaste Highlights Voting Results from Key US States and Grants Options – Momentum Public Relations – Press Release: November 9, 2016 Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N)(FRANKFURT:M5BQ) is pleased to report on the Company’s market position in the context of the recent voting results on […]...
    Read more
  • Namaste (N:CSE) Signs Definitive Agreement to Acquire URT1 Limited and Forms World's Largest E-Commerce B2C Vaporizer Company
    Namaste (N:CSE) Signs Definitive Agreement to Acquire URT1 Limited and Forms World’s Largest E-Commerce B2C Vaporizer Company
    September 15, 2016 by
    Namaste Signs Definitive Agreement to Acquire URT1 Limited and Forms World’s Largest E-Commerce B2C Vaporizer Company  VANCOUVER, BRITISH COLUMBIA–(Marketwired – Sept. 15, 2016) – Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N)(FRANKFURT:M5BQ) reports that it has entered into a Definitive Asset Purchase Agreement (the “Agreement”) with URT1 […]...
    Read more
  • Namaste (N:CSE) Increases Site Traffic by 531% From April to July
    Namaste (N:CSE) Increases Site Traffic by 531% From April to July
    August 17, 2016 by
    Namaste (N:CSE) Increases Site Traffic by 531% From April to July – Momentum Public Relations – Press Release: August 17, 2016 Namaste Technologies Inc. (CSE:N)(OTC PINK:NXTTF)(FRANKFURT:M5BQ) (“Namaste” or the “Company”) has increased its site traffic from 42,353 in April to 267,144 in July, an increase of 531% […]...
    Read more
  • Namaste Technologies (N:CSE) Announces Third Quarter Financial Results
    Namaste Technologies (N:CSE) Announces Third Quarter Financial Results
    August 3, 2016 by
    Namaste Technologies (N:CSE) Announces Third Quarter Financials Results – Momentum Public Relations – Press Release: August 3, 2016 Namaste Technologies Inc. (CSE:N)(OTC PINK:NXTTF)(FRANKFURT:M5BQ) (“Namaste” or the “Company”) has reported financial results for the third quarter and nine month period, each ending May 31, 2016. The financial statements […]...
    Read more
  • Cell Preservation Research - A New Frontier
    Cell Preservation Research – A New Frontier
    August 2, 2016 by
    CELL PRESERVATION RESEARCH – A NEW FRONTIER – Momentum Public Relations – “The planet’s hope and salvation lies in the adoption of revolutionary new knowledge being revealed at the frontiers of science”  – Bruce Lipton Although Dr. Lipton may not be universally revered in mainstream science, his […]...
    Read more
  • Namaste Closes Acquisition of VaporSeller
    Namaste Closes Acquisition of VaporSeller
    July 18, 2016 by
    Namaste Closes Aquisition of VaporSeller – Momentum Public Relations – Press Release: June 7, 2016 Namaste Technologies Inc. (CSE:N) (OTC PINK:NXTTF) (FRANKFURT:M5BQ) reports that it has completed the acquisition of VaporSeller, an e-commerce portal for the sale of vaporizers and accessories that generated an unaudited revenue base of […]...
    Read more
  • Relevium Announces Private Placement by Maestro Capital
    Relevium Announces Private Placement by Maestro Capital
    July 6, 2016 by
    Relevium Announces Private Placement by Maestro Capital – Momentum Public Relations – Press Release: July 6, 2016 Relevium Technologies Inc. (TSX VENTURE:RLV)(FRANKFURT:6BX) in conjunction with Maestro Capital Inc. (TSX.P – “MCP”) is pleased to announce that the two parties have agreed to the terms of participation by Maestro in […]...
    Read more
  • The Fountain of Youth
    Sirona Biochem (SBM:tsxv) CEO’s Report on Progress
    June 30, 2016 by
    Sirona Biochem CEO’s Report on Progress – Momentum Public Relations – June 30, 2016 Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) today provided a business update. Dear Shareholders, I would like to provide an update on our progress. As we enter Q3, our resources […]...
    Read more
  • Namaste Ranked as #1 E-Commerce Vaporizer Portal Globally
    Namaste Ranked as #1 E-Commerce Vaporizer Portal Globally
    June 28, 2016 by
    Namaste Ranked as #1 E-Commerce Vaporizer Portal Globally – Momentum Public Relations – Press Release: June 28, 2016 Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N)(OTC PINK:NXTTF)(FRANKFURT:M5BQ), a leading international vaporizers and accessories e-commerce company based on customer trustworthiness and service quality, reports on recent positive developments […]...
    Read more
  • Sirona Biochem Announces Positive Safety and Efficacy Data for Innovative Skin Lightening Compound
    Sirona Biochem Announces Positive Safety and Efficacy Data for Innovative Skin Lightening Compound
    June 16, 2016 by
    Sirona Biochem Announces Positive Safety and Efficacy Data for Innovative Skin Lightening Compound SBM-TFC-1067 Accepted as Abstract Presentation by IMCAS – Momentum Public Relations – June 16th, 2016 Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the “Company“) announced positive preclinical safety and efficacy data […]...
    Read more
  • INMED ANNOUNCES APPOINTMENT OF WILLIAM J. GARNER, M.D. TO ITS BOARD OF DIRECTORS
    INMED ANNOUNCES APPOINTMENT OF WILLIAM J. GARNER, M.D. TO ITS BOARD OF DIRECTORS
    June 13, 2016 by
    INMED ANNOUNCES APPOINTMENT OF WILLIAM J. GARNER, M.D. TO ITS BOARD OF DIRECTORS – Momentum Public Relations – June 13th, 2016 InMed Pharmaceuticals Inc. (“InMed” or “the Company”) (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, is […]...
    Read more
  • Sirona (SBM:tsxv) Announces Wanbang to Proceed with Pre-IND and Milestone Payment
    Sirona (SBM:tsxv) Announces Wanbang to Proceed with Pre-IND and Milestone Payment
    June 13, 2016 by
    Sirona Biochem Announces Wanbang Biopharmaceuticals to Proceed to Pre-IND Testing and Receipt of $300,000 USD Milestone Payment – Momentum Public Relations – June 13th, 2016 Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the “Company“) today announced that Wanbang Biopharmaceuticals has confirmed they will be […]...
    Read more
  • Namaste Signs Definitive Agreement for Acquisition of VaporSeller and Announces Private Placement
    Namaste Signs Definitive Agreement for Acquisition of VaporSeller and Announces Private Placement
    June 7, 2016 by
    Namaste Signs Definitive Agreement for Acquisition of VaporSeller and Announces Private Placement – Momentum Public Relations – Press Release: June 7, 2016 Namaste Technologies Inc. (CSE:N)(FRANKFURT:M5BQ) reports that further to its announcement on April 14, 2016, the Company has signed an Asset Purchase Agreement (the “Agreement”) dated June 7, […]...
    Read more
  • Namaste Launches Online Investor Relations Activities with AGORACOM
    Namaste Launches Online Investor Relations Activities with AGORACOM
    June 6, 2016 by
    Namaste Launches Online Investor Relations Activities with AGORACOM – Momentum Public Relations – Press Release: June 6, 2016 Namaste Technologies Inc. (CSE:N)(OTC PINK:NXTTF)(FRANKFURT:M5BQ) reports that it is implementing an online financial marketing and awareness program through AGORACOM. As a Company with significant online experience, Namaste’s management team views […]...
    Read more
  • Namaste Announces Commercialization of Grizzly Guru Vaporizer
    Namaste Announces Commercialization of Grizzly Guru Vaporizer
    May 30, 2016 by
    Namaste Announces Commercialization of Grizzly Guru Vaporizer – Momentum Public Relations – Press Release: May 30, 2016 Namaste Technologies Inc. (CSE:N)(OTC PINK:NXTTF)(FRANKFURT:M5BQ) reports the launching of the Gurutm vaporizer, a handheld portable vaporizer that provides a seamless solution for vaporizing dry herbs, concentrates and liquids. The Gurutm will […]...
    Read more
  • Relevium Technologies Signs LOI to Acquire a Controlling Interest in a Montreal-Based Distribution Company
    Relevium Technologies Signs LOI to Acquire a Controlling Interest in a Montreal-Based Distribution Company
    May 19, 2016 by
    Relevium Technologies Signs LOI to Acquire a Controlling Interest in a Montreal-Based Distributuon Company – Momentum Public Relations – Press Release: May 19, 2016 Relevium Technologies Inc. (TSX VENTURE:RLV)(FRANKFURT:6BX) is pleased to announce it has executed a letter of intent to acquire a controlling interest and progressively 100% […]...
    Read more
  • Namaste Expands Wholesale and E-Commerce Platforms
    Namaste Expands Wholesale and E-Commerce Platforms
    May 16, 2016 by
    Namaste Expands Wholesale and E-Commerce Platforms – Momentum Public Relations – Press Release: May 16, 2016 Namaste Technologies Inc. (CSE:N)(OTC PINK:NXTTF) (FRANKFURT:M5BQ) reports the launch of a new wholesale division, the development of multiple new e-commerce and social media platforms specifically designed for the vaporizer and accessories community, […]...
    Read more
  • Relevium Technologies Returns 8,612,500 Shares to Treasury
    Relevium Technologies Returns 8,612,500 Shares to Treasury
    April 22, 2016 by
    Relevium Technologies Returns 8,612,500 Shares to Treasury – Momentum Public Relations – Press Release: April 22, 2016 Relevium Technologies Inc. (TSX VENTURE:RLV)(FRANKFURT:6BX) is pleased to announce it has received approval from the TSX Venture Exchange (the “Exchange”) regarding the cancellation of 8,612,500 previously issued shares relating to […]...
    Read more
  • Sirona Biochem (SBM.V) Initiates Research and Development on New Therapies
    Sirona Biochem (SBM.V) Initiates Research and Development on New Therapies
    April 18, 2016 by
    Sirona Biochem Initiates Research and Development on New Therapies for Keloid Scars and Acne Vulgar – Momentum Public Relations – April 18, 2016 Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the “Company“) announces that its CEO, Dr. Howard Verrico, has approved two new therapeutic projects within […]...
    Read more
  • Sirona Biochem Begins Cell Preservation Research
    Sirona Biochem Begins Cell Preservation Research
    April 11, 2016 by
    Sirona Biochem (SBM:tsxv) Begins Cell Preservation Research Collaboration With Dr. Caigan Du, University of British Columbia – Momentum Public Relations – April 11, 2016 Sirona Biochem Corp. (SBM:tsxv) (ZSB:Frankfurt) (ZSB: Xetra) (the “Company“) announces that it has entered into a research collaboration with Dr. Caigan Du of the University […]...
    Read more
  • Relevium Technologies Provides Corporate Update
    Relevium Technologies Provides Corporate Update
    April 6, 2016 by
    Relevium Technologies Provides Corporate Update – Momentum Public Relations – Press Release: April 6, 2016 Relevium Technologies Inc. (TSX VENTURE:RLV)(FRANKFURT:6BX) is pleased to provide an update regarding the previously announced corporate roll-up strategy, focused on acquiring products, technologies or companies within the rapidly expanding global health and wellness […]...
    Read more
  • Namaste Announces Management and Board Appointments
    Namaste Announces Management and Board Appointments
    April 4, 2016 by
    Namaste Announces Management and Board Appointments – Momentum Public Relations – Press Release: April 4, 2016 Namaste Technologies Inc. (CSE:N)(OTC PINK:NXTTF)(FRANKFURT:M5BQ) announces the appointment of Mr. Sidney Himmel as Chairman of the Board of Directors of the Company and Mr. Darren Collins as CFO of the Company, effective […]...
    Read more
  • Relevium Technologies Enters Into Exclusive Supply Agreement
    Relevium Technologies Enters Into Exclusive Supply Agreement
    April 4, 2016 by
    Relevium Technologies Enters Into Exclusive Supply Agreement – Momentum Public Relations – Press Release: April 4, 2016 Relevium Technologies Inc. (TSX VENTURE: RLV) (FRANKFURT: 6BX) is pleased to provide an update on its corporate strategy, which is primarily focused on the acquisition of products or companies within three […]...
    Read more
  • Sirona Biochem Selected to Present at BIO-Europe Spring
    Sirona Biochem Selected to Present at BIO-Europe Spring
    March 21, 2016 by
    Sirona Biochem Selected to Present at BIO-Europe Spring – Momentum Public Relations – March 21, 2016 Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the “Company“) announces that its Chief Business Development Officer, Attila Hajdu, will be presenting at BIO-Europe Spring on April 4, 2016, at 10:00 […]...
    Read more
  • Target Price for Sirona Biochem (SBM:tsxv) 0.98$
    Target Price for Sirona Biochem (SBM:tsxv) 0.98$
    March 10, 2016 by
    Sirona Biochem (SBM:tsxv) Gets BUY Rating : Target Price CAD 0.98$ – Momentum Public Relations – Yesterday, First Berlin Equity Research published a research update on Sirona Biochem Corp. (SBM:tsxv). Analyst Ellis Acklin reiterated his BUY rating and increased  the price target from CAD 0.90 to CAD […]...
    Read more
  • Sirona Biochem: The Leader in Carbohydrate Stabilization Technology
    Sirona Biochem: The Leader in Carbohydrate Stabilization Technology
    January 28, 2016 by
    Sirona Biochem: The Global Leader in Carbohydrate Stabilization Technology – Momentum Public Relations – Sirona Biochem (SBM:tsxv) is a proactive development and discovery stage based biotech firm with an R&D lab situated in Paris, France. The biotechnology enterprise is headquartered in Vancouver, British Columbia in Canada, and […]...
    Read more
  • Medical Marijuana - 8 Uses of Cannabinoids
    Medical Marijuana – 8 Uses of Cannabinoids
    January 25, 2016 by
    Medical Marijuana – 8 Uses of Cannabinoids  – Momentum Public Relations – Canada has come a long way in regards to medical marijuana. It wasn’t that long ago that any mention of marijuana automatically conjured an image of a stereotypical stoner eating snacks on the couch. As […]...
    Read more
  • Sirona Presents New Results From Glycoprotein Program at BIO-Europe
    Sirona Presents New Results From Glycoprotein Program at BIO-Europe
    October 26, 2015 by
    Sirona Biochem Presents New Results From Glycoprotein Program at BIO-Europe Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (the “Company“) announces that its Chief Business Development Officer, Attila Hajdu, will be presenting at BIO-Europe on November 4, 2015, at 10:15 am GMT at the International Congress Centre […]...
    Read more
  • First Berlin - Sirona Biochem Corp. Research Update
    First Berlin – Sirona Biochem Corp. Research Update
    October 19, 2015 by
    First Berlin Equity Research has published a research update on Sirona Biochem Corp. (SBM:tsxv) (ISIN: CA82967M1005). Analyst Ellis Acklin reiterated his BUY rating and maintained his CAD 0.90 price target. This is an abbreviated summary. The full text of this story is included just below. Abstract: Sirona published […]...
    Read more
  • Inmed (IN:CSE) CEO's Letter to Shareholders & Corporate Presentation
    Inmed (IN:CSE) CEO’s Letter to Shareholders & Corporate Presentation
    October 6, 2015 by
    Letter from President and CEO Dear Shareholder, As the new President and CEO at InMed, I’m reaching out to you to provide you with my impressions after my first 3 weeks at the company, and to give you some insight into what I see as the operational […]...
    Read more
  • Sirona featured in Cosmetics Design USA
    Sirona featured in Cosmetics Design USA
    September 30, 2015 by
    Yesterday CosmeticsDesign.com  featured Sirona Biochem (SBM:tsxv) in an article highlighting the biotechnological  advancements they’ve made in the development of a Skin Lightener which has already begun generating big interest from some of the world’s top cosmetic companies.  The Skin Lightener market is forecasted to be worth 19.8 […]...
    Read more
  • Sirona to Attend Cosmetic360 Conference in Paris
    Sirona to Attend Cosmetic360 Conference in Paris
    September 24, 2015 by
    Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the “Company“) announces that it will attend Cosmetic360 in Paris, France, October 15-16, 2015. Cosmetic360 is an innovative trade forum for the cosmetic industry. The conference brings together professionals and industry representatives from all over the world. […]...
    Read more
  • Sirona Biochem (SBM:tsxv) Investor Event
    September 23, 2015 by
    Sirona met with Investors and Brokers at Canaccord in Vancouver on September 15th, 2015. This is the most recent corporate presentation that was put together for this recent Investor Event. You will find current collaborations, what they have in the pipeline, and the revenue growth potential. Sirona’s […]...
    Read more
  • Sirona Biochem finishes scale-up of SBM-TFC-1067
    September 15, 2015 by
    Sirona Biochem (SBM.V) Reaches Major Milestone by Successful Scale-Up of Skin Lightening Compound SBM-TFC-1067 Formulation Testing by Potential Licensee Gets Underway Shortly Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB.DE), (the “Company“) is pleased to announce the successful scale-up of its skin lightening compound SBM-TFC-1067 […]...
    Read more
  • Sirona Biochem (SBM:tsxv) receives approval to trade on Xetra
    September 11, 2015 by
    SIRONA BIOCHEM APPOINTS GERMAN PRIVATE BANK HAUCK & AUFHAUSER AS DESIGNATED SPONSOR FOR XETRA(R) Sirona Biochem Corp.’s (SBM:tsxv) shares have been accepted for continuous trading on the German electronic trading platform Xetra under the ticker symbol ZSB.DE. The International Security Identification Number (ISIN) is CA82967M1005. The electronic […]...
    Read more
  • InMed Pharmaceuticals Appoints New CEO
    September 3, 2015 by
    InMed Appoints Paul Brennan as President & Chief Executive Officer InMed Pharmaceuticals Inc. (“InMed” or “the Company”) (CSE: IN)(OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announced today that Paul Brennan, a 25-year veteran […]...
    Read more
  • InMed Pharma Starts Testing Drug Delivery System
    September 2, 2015 by
    InMed Commences Development of Proprietary Drug Delivery System InMed Pharmaceuticals Inc. (“InMed”) (CSE: IN)(OTCQB: IMLFF) is pleased to announce it has initiated testing of a novel nanoparticle based delivery system for INM-750 which will be used for clinical formulations. INM-750 is a proprietary phytocannabinoid based compound for […]...
    Read more
  • InMed Appoints Paul Brennan to the Board of Directors
    August 25, 2015 by
    InMed Pharmaceuticals Inc. (“InMed” or “the Company”) (CSE: IN)(OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announced today the appointment of Paul Brennan to the Company’s Board of Directors. Mr. Brennan brings more than […]...
    Read more
  • InMed Announces Positive In-Vitro Study Results
    August 6, 2015 by
    InMed Announces Positive In-Vitro Study Results of INM-750 Targeting Epidermolysis Bullosa Simplex (EBS) InMed Pharmaceuticals Inc. (“InMed”) (CSE: IN)(OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announced today that it has obtained positive response […]...
    Read more
  • Cannabionoid Medicines – Beginner’s Guide To Endocannabinoid’s
    June 11, 2015 by
    Cannabinoid Medicines – Investors are on Watch as this New Industry Develops. Governments, health institutions, marijuana patients and marijuana enthusiasts alike have been buzzing about the recent changes regarding cannabis, on both the recreational and medicinal levels.  The momentum behind the developments in the legalized cannabis industry […]...
    Read more
  • InMed Looks into Treating COPD with Cannabinoids
    June 3, 2015 by
    InMed Adds Chronic Obstructive Pulmonary Disease (COPD) Program to Therapeutic Pipeline InMed Pharmaceuticals Inc. (“InMed”) (IN:CSE)(IMLFF:OTCQB), a clinical stage biopharmaceutical company that specializes in developing safer, more effective cannabis-based therapies, announced it has initiated a program to identify and evaluate cannabinoid compounds for the treatment of chronic […]...
    Read more
  • InMed applies to patent EPS treatment in U.S.
    May 26, 2015 by
    INMED PHARMACEUTICALS FILES PROVISIONAL PATENT COVERING NOVEL COMPOUNDS FOR TREATING EPIDERMOLYSIS BULLOSA SIMPLEX (EBS) InMed Pharmaceuticals Inc. (“InMed”) (IN:CSE ; IMLFF:OTC), announced today that it has filed a provisional patent application with the United States Patent and Trademark Office (“USPTO”) relating to the treatment of Epidermolysis Bullosa […]...
    Read more
  • InMed hires Peter Mountford as Strategic Adviser
    May 5, 2015 by
    INMED (IN:CSE) ENGAGES PETER MOUNTFORD AS STRATEGIC ADVISOR 2015-05-05  – News Release – Former GW Pharmaceuticals financier, investor and non-executive director Peter Mountford has agreed to support InMed Pharmaceuticals Inc. as strategic adviser with primary responsibility for the European markets. In this role, Mr. Mountford will leverage […]...
    Read more
  • InMed Awarded Mitacs Grant for Proprietary Glaucoma Therapy
    April 15, 2015 by
    INMED AWARDED GRANT FOR PROPRIETARY NANOPARTICLE-BASED DELIVERY SYSTEM FOR GLAUCOMA THERAPY News Release – April 15, 2015 – InMed Pharmaceuticals Inc. (“InMed”) (CSE: IN; OTCQB: IMLFF), a clinical stage biopharmaceutical company that specializes in developing safer, more effective cannabinoid-based therapies, today announced that it has been awarded a […]...
    Read more
  • InMed Pharmaceuticals arranges $1-million financing
    April 6, 2015 by
    2015-04-06 11:25 ET – News Release Mr. Craig Schneider reports INMED PHARMACEUTICALS, INC. ANNOUNCES NON-BROKERED PRIVATE PLACEMENT FOR UP TO C$1,000,000 InMed Pharmaceuticals Inc. will conduct a non-brokered private placement of up to four million units at a price of 25 cents per unit for aggregate gross […]...
    Read more
  • InMed appoints Anderson to Scientific Advisory Board
    March 31, 2015 by
    INMED PHARMACEUTICALS STRENGTHENS SCIENTIFIC ADVISORY BOARD 2015-03-31 – News Release – InMed Pharmaceuticals Inc. (IN:CSE) has appointed Dr. Paul C. Anderson, PhD, to its scientific advisory board. Dr. Anderson is a pharma industry veteran who brings significant drug discovery and development expertise to InMed. Dr. Anderson is […]...
    Read more
  • InMed Gains Health Canada Exemption for Cannabinoid Use
    March 23, 2015 by
    2015-03-23 08:12 ET – News Release (Marketwired) INMED RECEIVES EXEMPTION STATUS FROM HEALTH CANADA InMed Pharmaceuticals Inc. (CSE:IN, OTCQB:IMLFF) has received a notice from Health Canada dated March 12, 2015, approving InMed’s application for an exemption under Section 56 of the Controlled Drugs and Substances Act. This […]...
    Read more
  • InMed Begins Preclinical Work on Orofacial Pain
    March 18, 2015 by
    2015-03-18 – News Release – InMed Pharmaceuticals Inc. (IN:CSE) has initiated a program to identify and evaluate cannabinoid compounds for the treatment of chronic orofacial pain. Initial drug discovery and preclinical development are currently under way in collaboration with members of the faculty of pharmaceutical sciences at […]...
    Read more
  • Patients vs Government -The Battle for Medical Marijuana
    March 17, 2015 by
    By: Frehiwote Negash – It’s been nearly a year since the Medical Marijuana Purposes Regulation has gone into effect and the debate over who has the “right to grow” has shift into a legal battle about patients’ rights and accessibility versus government oversight. The fight for medical […]...
    Read more
  • InMed Forms Strategic Collaboration to Develop PhytoCannabinoid Therapies
    March 10, 2015 by
    2015-03-10 – News Release – InMed Pharmaceuticals Inc. (IN:CSE) has formed an exclusive strategic collaboration with the University of Debrecen, Hungary, to develop novel phytocannabinoid-based therapies to treat ocular allergic symptoms. The collaboration will leverage InMed’s proprietary intelligent cannabinoid drug design platform (IDP) and will be led […]...
    Read more
  • Sirona’s Partner Completes SBM-TFC-039 Toxicology Test
    March 4, 2015 by
    Positive Preclinical Toxicology Results for its SGLT2 Inhibitor Trigger Milestone Payment from Wanbang Biopharmaceuticals Sirona Biochem Corp. (TSX VENTURE: SBM) today announced that Wanbang Biopharmaceuticals has successfully completed the toxicology study in the pre-clinical validation of its anti-diabetic SGLT2 Inhibitor, SBM-TFC-039, for the treatment of Type 2 […]...
    Read more
  • InMed Pharmaceuticals on the Rise
    March 4, 2015 by
    By Frehiwote Negash – As the marijuana debate continues to dominate headlines on both sides of the border, there are emerging players that have taken the pharmaceutical approach by developing therapeutic options using cannabinoids and testing their effectiveness via clinical trials. As marijuana gains traction as a […]...
    Read more
  • InMed Pharmaceuticals (IN:CSE) Appoints Dr. Abo Mohammed as Chief Medical Officer
    March 4, 2015 by
       Inmed Pharmaceuticals announced today that it has appointed former Associate Medical Director of GW Pharmaceuticals, Abo Mohammed – VANCOUVER, British Columbia, March 4, 2015 /PRNewswire/ — InMed Pharmaceuticals, Inc. (“InMed”) (CSE: IN; OTCQB: IMLFF), a clinical stage biopharmaceutical company specializing in the development of cannabinoid based therapies, […]...
    Read more
  • InMed Expands Pipeline with Initiation of Program Targeting Epidermolysis bullosa simplex (EBS)
    February 3, 2015 by
    Vancouver, BC — February 3, 2015- InMed Pharmaceuticals Inc. (“InMed”) (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announced today that it has added a new therapy to its pipeline: INM-750, for […]...
    Read more
  • Sirona Subsidiary, TFChem, Receives CDN$1.2 Million for Anti-Aging Project
    August 21, 2014 by
    VANCOUVER, BC–(Marketwired – August 12, 2014) – Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB), (the “Company”) announced that its French subsidiary, TFChem, has received confirmation for funding of CDN$1.2 million from Bpifrance (the French Public Investment Bank) and the district of Haute Normandie in […]...
    Read more
  • Sirona Biochem Launches Global Awareness Campaign With Cousteau Ambassadors’ Video
    August 21, 2014 by
    VANCOUVER, BC, Aug 21, 2014 (Marketwired via COMTEX) — Sirona Biochem Corp. (SBM) (frankfurt:ZSB) launches global awareness campaign with ambassadors’ video produced by the team of Jean-Michel Cousteau and Fabien Cousteau to represent their support of the glycoprotein project. “The time and effort put into this video […]...
    Read more
  • If Big Pharma Isn’t Nervous, It Should Be; Early Stage Cannabis Technologies…Potentially the Next GW Pharma
    July 31, 2014 by
    VANCOUVER, British Columbia, July 31, 2014 (GLOBE NEWSWIRE) — Deep in the brain, buried within the central nervous system as well as lymphatic tissues and organs throughout the body are cannabinoid receptors; patiently waiting to help address a myriad of diseases. With the advent of cannabis research […]...
    Read more
  • Sirona, Bloom Burton makes anti-inflammatory compound
    July 31, 2014 by
    Mr. Howard Verrico reports SIRONA BIOCHEM ANNOUNCES SUCCESSFUL SYNTHESIS OF ANTI-INFLAMMATORY COMPOUND FOR BLOOM BURTON & CO. JOINT VENTURE Sirona Biochem Corp. has achieved the first batch of compound in the joint venture with Bloom Burton & Co. Compounds developed within the framework of the JV will […]...
    Read more
  • SIRONA ARRANGES CONVERTIBLE LOANS
    July 30, 2014 by
    Sirona Biochem Corp. (SBM.V) has entered into convertible loan agreements with arm’s-length parties for the purposes of renewing current outstanding loans in the total amount of $670,000. The original loans were taken out in late 2012 and became due this quarter. The new loans are secured by […]...
    Read more
  • Stand-in CEO insists that Sirona Biochem hasn’t lost its focus
    July 29, 2014 by
    Sirona Biochem announces it will continue to focus on the skin care market and develop new active ingredients for the cosmetics market, and will be unaffected by its change in management.   Last month company CEO Neil Belenkie resigned from the company and with Howard Verrico taking […]...
    Read more
  • Sirona licensee completes two SBM-TFC-039 studies
    July 24, 2014 by
    <p>SIRONA BIOCHEM ANNOUNCES SUCCESSFUL COMPLETION OF TWO FIRST LINE STUDIES BY WANBANG BIOPHARMACEUTICALS</p> <p>Sirona Biochem Corp. has provided an update. Wanbang Biopharmaceuticals has completed two preclinical efficacy studies of the SGLT2 inhibitor SBM-TFC-039. The studies independently confirm that SBM-TFC-039 increased urinary glucose excretion and improved oral glucose […]...
    Read more
  • Sirona Biochem Corporation - CEO Letter to Shareholders
    Sirona Biochem Corporation – CEO Letter to Shareholders
    July 24, 2014 by
    <p id=”yui_3_16_0_1_1406034781965_1472″><span style=”font-family: arial; font-size: 12pt;”><span id=”yui_3_16_0_1_1406034781965_1471″ class=”mw_region”>VANCOUVER, BC</span>–(Marketwired – July 21, 2014) – Sirona Biochem Corp. <span class=”mw_ticker”>(TSX VENTURE: SBM)</span> <span class=”mw_ticker”>(<a href=”http://finance.yahoo.com/q?s=srbcf” data-rapid_p=”8″>SRBCF</a>)</span> <span class=”mw_ticker”>(<a href=”http://finance.yahoo.com/q?s=zsb.f” data-rapid_p=”9″>ZSB.F</a>)</span> today provided a business update. </span></p> <p id=”yui_3_16_0_1_1406034781965_1479″><span style=”font-family: arial; font-size: 12pt;”>Dear Shareholders and Investors,</span></p> <p id=”yui_3_16_0_1_1406034781965_1481″><span style=”font-family: […]...
    Read more
  • SIRONA BIOCHEM CORPORATION - CEO LETTER TO SHAREHOLDERS
    SIRONA BIOCHEM CORPORATION – CEO LETTER TO SHAREHOLDERS
    July 22, 2014 by
    Sirona Biochem Corp. has provided a business update in the form of a shareholders letter from the chief executive officer. Dear shareholders and investors, As announced in our recent news release, I, Howard Verrico, have stepped in as chief executive officer of Sirona Biochem. Although this change […]...
    Read more
  • Sirona hires PRC Partners for consulting services
    July 22, 2014 by
    <p>SIRONA ANNOUNCES SHARES FOR SERVICES AGREEMENT</p> <p>Sirona Biochem Corp. has entered into a business consulting agreement with PRC Partners Ltd. of Hong Kong for a six-month term commencing July 15, 2014. As compensation for the services to be provided, PRC will receive a total of 1,500,000 common […]...
    Read more
Please wait...

Knowledge is Power

Knowledge is a necessity for all savvy investors. To achieve great CONSISTENT returns, smart investors know they need all the information they can get. We have your information!